Interestingly, the lidERA breast cancer trial and CAMBRIA 2 trials are phase III randomized trials of adjuvant giredestrant (lidERA) or camizestrant (CAMBRIA 2) vs. the adjuvant standard endocrine therapy of the physician’s choice among patients with a history of medium- to high-risk ER+ HER2− breast cancer (NCT04961996, NCT05952557). The gene discussed is ESR1; the disease is breast cancer.